Table 4.

Adverse events in patients with advanced renal cell carcinoma and melanoma treated with ipilimumab plus nivolumab.

Events	Renal Cell Carcinoma (n = 36)		Melanoma (n = 35)
	Any	Grade 3–4	Any	Grade 3–4
	number of patients with event (percent)
Diarrhea	7 (19.4)	1 (2.8)	0	0
Colitis	2 (5.6)	0	2 (5.7)	2 (5.7)
Hepatitis	2 (5.6)	1 (2.8)	13 (37.1)	3 (8.6)
Increase in lipase level	1 (2.8)	1 (2.8)	2 (5.7)	0
Pancreatitis	1 (2.8)	0	0	0
Autoimmune sclerosing cholangitis	2 (5.6)	1 (2.8)	0	0
Pruritus	7 (19.4)	0	14 (40.0)	1 (2.9)
Rash	0	0	15 (42.9)	3 (8.6)
Vitiligo	0	0	20 (57.1)	0
Drug Rash with Eosinophilia and Systemic Symptoms	0	0	1 (2.9)	0
Hypophysitis	2 (5.6)	1 (2.8)	8 (22.9)	2 (5.7)
Diabetes mellitus	0	0	3 (8.6)	0
Thyroiditis	6 (16.7)	0	6 (17.1)	0
Interstitial diffuse lung disease	4 (11.1)	3 (8.3)	0	0
Sarcoidosis	0	0	1 (2.9)	0
Myositis	2 (5.6)	1 (2.8)	1 (2.9)	1 (2.9)
Myocarditis	1 (2.8)	1 (2.8)	0	0
Nephritis	0	0	3 (8.6)	1 (2.9)
Arthralgia	3 (8.3)	2 (5.6)	5 (14.3)	2 (5.7)
Aseptic meningitis	2 (5.6)	2 (5.6)	4 (11.4)	4 (11.4)
Peripheral neuropathy	0	0	3 (8.6)	2 (5.7)
Uveitis	0	0	4 (11.4)	1 (2.9)
Treatment-related adverse event leading to discontinuation	5 (13.9)	5 (13.9)	13 (37.1)	9 (25.7)